Apidra doesn’t warrant its own line in Sanofi’s financial reports, and the reductions don’t include Sanofi's Toujeo, a more concentrated version of insulin glargine that offers less frequent ...

One group received two oral drugs (metformin plus the sulfonylurea glimepiride [Amaryl]) plus morning doses of glargine insulin (Lantus); the other group received twice-daily premixed insulin (70% ...

The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...

New insulin analogues such as the long-acting analogue insulin glargine may represent beneficial treatment options in pregnancy by ensuring that patients achieve excellent glycemic control without ...

The growth trajectory of the Apidra market is closely linked to the rising prevalence of diabetes, which is accelerating demand for rapid-acting insulin treatments like Apidra. Diabetes ...